Safety of an Aspirin-Alone Regimen After Intracoronary Stenting With a Heparin-Coated Stent
Key result
The use of a heparin-coated stent (HEPACOAT) followed by aspirin monotherapy resulted in a 30-day stent thrombosis rate of 1% in patients with native coronary artery lesions.
Why the study?
Is an aspirin-alone regimen safe after intracoronary stenting with a heparin-coated stent in patients with native coronary artery lesions?
Population
200 patients with de novo or restenotic native coronary artery lesions, mean age 64.1, 69% men.
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
May support aspirin monotherapy after heparin-coated stenting in select patients; leaves open need for randomized confirmation of safety.
Structured PICO
Is an aspirin-alone regimen safe after intracoronary stenting with a heparin-coated stent in patients with native coronary artery lesions?
P
Population
200 patients (mean age 64.1 years, 31% female) with de novo or restenotic native coronary artery lesions treated with a heparin-coated stent and aspirin monotherapy, followed for 30 days.
I
Intervention
Heparin-coated stent (BX VELOCITY with HEPACOAT) followed by aspirin monotherapy (no other antiplatelet or anticoagulation therapy permitted).
O
Outcome
Stent thrombosis at 30 dayssafety
Aspirin monotherapy after intracoronary stenting with a heparin-coated stent appears safe, with a low 30-day rate of stent thrombosis (1%) in select patients.
Cite This Study
Mehran et al. (2003) studied de novo or restenotic native coronary artery lesions (n=200). BX VELOCITY Balloon-Expandable Stent with HEPACOAT and aspirin monotherapy was evaluated on stent thrombosis at 30 days. The use of a heparin-coated stent (HEPACOAT) followed by aspirin monotherapy resulted in a 30-day stent thrombosis rate of 1% in patients with native coronary artery lesions.